Главная

Врачи

Ховав Нехуштан

Отделение: Онкология

Должность: Онколог

Языки: Иврит, Английский

Принимает: только взрослых

Написать в WhatsApp Записаться на прием

Профессор Ховав Нехуштан. Директор центра лечения рака легких.

Научные публикации

Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report

The functional role of Nudt2 in human triple negative breast cancer

Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells

In Response

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy

Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Role of Nudt2 in Anchorage-Independent Growth and Cell Migration of Human Melanoma

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study

Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report

Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Liquid First Is "Solid" in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in Israel

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases

Long term follow-up of EGFR mutated NSCLC cases

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes

Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis

Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes

Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization

Ap₄A Regulates Directional Mobility and Antigen Presentation in Dendritic Cells

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients

Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells

Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients

PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer

FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer

Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report

EGFR mutation testing practice in advanced non-small cell lung cancer

A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients

Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis

Non-canonical roles of lysyl-tRNA synthetase in health and disease

Amino-acyl tRNA synthetases generate dinucleotide polyphosphates as second messengers: functional implications

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer

Structural switch of lysyl-tRNA synthetase between translation and transcription

Transcription factor E3, a major regulator of mast cell-mediated allergic response

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Pemetrexed-induced lung toxicity: a case report

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Importin beta plays an essential role in the regulation of the LysRS-Ap(4)A pathway in immunologically activated mast cells

Mast cell transcription factors--regulators of cell fate and phenotype

Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy

The enigma of the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response

The complexity of the complicity of mast cells in cancer

Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas

Chapter 1: The physiological role of lysyl tRNA synthetase in the immune system

Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy

LysRS serves as a key signaling molecule in the immune response by regulating gene expression

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations

A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells

Diadenosine tetraphosphate hydrolase is part of the transcriptional regulation network in immunologically activated mast cells

Mast cells and cancer--no longer just basic science

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo

Microphthalmia transcription factor isoforms in mast cells and the heart

Transcription factor MITF regulates cardiac growth and hypertrophy

Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells

Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3

Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas

c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells

The function of lysyl-tRNA synthetase and Ap4A as signaling regulators of MITF activity in FcepsilonRI-activated mast cells

A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival

Tamoxifen and breast cancer

The function of MITF and associated proteins in mast cells

A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor

Studies of different aspects of the role of protein kinase C in mast cells

Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta

Suppression of microphthalmia transcriptional activity by its association with protein kinase C-interacting protein 1 in mast cells

Deciphering the early-response transcription factor networks in mast cells

Nuclear translocation of upstream stimulating factor 2 (USF2) in activated mast cells: a possible role in their survival

Growth-dependent and PKC-mediated translational regulation of the upstream stimulating factor-2 (USF2) mRNA in hematopoietic cells

Analysis of cytokine profile in human colonic mucosal Fc epsilonRI-positive cells by single cell PCR: inhibition of IL-3 expression in steroid-treated IBD patients

Involvement of HNF-1 in the regulation of phosphoenolpyruvate carboxykinase gene expression in the kidney

Microphthalmia (mi) in murine mast cells: regulation of its stimuli-mediated expression on the translational level

Regulation of mast cell growth and proliferation

Murine and human mast cell express acetylcholinesterase

Regulation of AP-1 expression and activity in antigen-stimulated mast cells: the role played by protein kinase C and the possible involvement of Fos interacting protein

Differential regulation of the rat phosphoenolpyruvate carboxykinase gene expression in several tissues of transgenic mice

Separate cis-regulatory elements confer expression of phosphoenolpyruvate carboxykinase (GTP) gene in different cell lines

Glucocorticoids control phosphoenolpyruvate carboxykinase gene expression in a tissue specific manner

Показать ещё 107 статей Скрыть статьи

Заболевания

Рак легких

Остались вопросы?

Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы

Задать вопрос

Напишите нам по любому вопросу. Мы свяжемся с вами в течение ближайшего рабочего дня.

Нажимая на кнопку «Отправить», я соглашаюсь с политикой о персональных данных